Literature DB >> 3435108

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.

M Baba1, R Pauwels, J Balzarini, P Herdewijn, E De Clercq, J Desmyter.   

Abstract

The combined antiviral effects of various 2',3'-dideoxynucleosides and ribavirin on the replication of human immunodeficiency virus type 1 in MT-4 cells have been examined. Ribavirin antagonized the antiviral activity of the pyrimidine 2',3'-dideoxynucleosides (3'-azido-2',3'-dideoxythymidine, 2',3'-dideoxythymidin-2'-ene, 2',3'-dideoxycytidine, and 2',3'-dideoxycytidin-2'-ene), but enhanced the antiviral activity of the purine 2',3'-dideoxynucleosides (2',3'-dideoxyadenosine and 2',3'-dideoxyguanosine). Combinations of the 2',3'-dideoxynucleosides with each other were also examined. These combinations resulted in an additive to subsynergistic effect.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3435108      PMCID： PMC175001          DOI： 10.1128/AAC.31.10.1613

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus.

Authors:  R Pauwels; E De Clercq; J Desmyter; J Balzarini; P Goubau; P Herdewijn; H Vanderhaeghe; M Vandeputte
Journal:  J Virol Methods       Date:  1987-06       Impact factor: 2.014

3.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

4.  Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro.

Authors:  T S Lin; R F Schinazi; M S Chen; E Kinney-Thomas; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1987-02-01       Impact factor: 5.858

5.  Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.

Authors:  N K Ayisi; V S Gupta; J B Meldrum; A K Taneja; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

6.  Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine.

Authors:  J Balzarini; R Pauwels; P Herdewijn; E De Clercq; D A Cooney; G J Kang; M Dalal; D G Johns; S Broder
Journal:  Biochem Biophys Res Commun       Date:  1986-10-30       Impact factor: 3.575

7.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes.

Authors:  J B McCormick; J P Getchell; S W Mitchell; D R Hicks
Journal:  Lancet       Date:  1984-12-15       Impact factor: 79.321

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

Authors:  J Balzarini; G J Kang; M Dalal; P Herdewijn; E De Clercq; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1987-07       Impact factor: 4.436
View more
  45 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

3.  Exploiting drug repositioning for discovery of a novel HIV combination therapy.

Authors:  Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.

Authors:  H Ma; S Le Pogam; S Fletcher; F Hinojosa-Kirschenbaum; H Javanbakht; J-M Yan; W-R Jiang; N Inocencio; K Klumpp; I Nájera
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 7.  Zalcitabine. Clinical pharmacokinetics and efficacy.

Authors:  D Devineni; J M Gallo
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

8.  The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Authors:  Rima Kulkarni; Rebecca Hluhanich; Damian M McColl; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05

10.  3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation.

Authors:  R W Buckheit; J Germany-Decker; K Qualls-Goodwin; B J Bowdon; W M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.